Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Vanderbilt-Ingram Cancer Center.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT00550537
First received: October 26, 2007
Last updated: July 20, 2011
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)